Postmenopausal hormone replacement and venous thromboembolism following hip and knee arthroplasty

Jason G. Hurbanek, Amir K. Jaffer, Nariman Morra, Matthew Karafa, Daniel Brotman

Research output: Contribution to journalArticle

Abstract

Hormone replacement therapy has been associated with venous thromboembolism. Controversy exists regarding the appropriate management of hormone replacement in the perioperative setting and in other situations - such as acute illness - predisposing to acute venous thromboembolism. We performed a case-control study to determine whether perioperative hormone replacement is associated with venous thromboembolism following hip and knee arthroplasty. 108 patients with postoperative venous thrombosis were matched by age, date and type of surgery, and surgeon with 210 controls without thrombosis. Perioperative hormone replacement use was no more prevalent in patients with postoperative thrombosis than those without. Eighteen (16.7%) women with post-operative thrombosis had taken perioperative hormone replacement compared to 49 (23.3%) of controls: odds ratio = 0.66; (95% CI 0.35-1.18; p=0.17). After multivariate analysis, the adjusted odds ratios were similar. Variables predicting post-operative thrombosis included: prior venous thromboembolism (OR = 2.3; p = 0.02), rheumatologic disease (OR = 2.2; p = 0.03), and absence of pharmacologic antithrombotic prophylaxis (OR = 13.4; p = 0.005). Cases and controls were otherwise similar. Users of hormone replacement were similar to non-users except that they were less likely to have coronary disease (OR 0.34; p = 0.03) or prior thrombosis (OR = 0.28; p = 0.04), and were younger (median age 67 versus 74 years; p

Original languageEnglish (US)
Pages (from-to)337-343
Number of pages7
JournalThrombosis and Haemostasis
Volume92
Issue number2
StatePublished - Aug 2004
Externally publishedYes

Fingerprint

Knee Replacement Arthroplasties
Venous Thromboembolism
Hip
Thrombosis
Hormones
Odds Ratio
Hormone Replacement Therapy
Venous Thrombosis
Coronary Disease
Case-Control Studies
Multivariate Analysis

Keywords

  • Arthroplasty
  • Hormone replacement therapy
  • Selective oestrogen receptor modulator
  • Surgery
  • Venous thromboembolism

ASJC Scopus subject areas

  • Hematology

Cite this

Postmenopausal hormone replacement and venous thromboembolism following hip and knee arthroplasty. / Hurbanek, Jason G.; Jaffer, Amir K.; Morra, Nariman; Karafa, Matthew; Brotman, Daniel.

In: Thrombosis and Haemostasis, Vol. 92, No. 2, 08.2004, p. 337-343.

Research output: Contribution to journalArticle

Hurbanek, Jason G. ; Jaffer, Amir K. ; Morra, Nariman ; Karafa, Matthew ; Brotman, Daniel. / Postmenopausal hormone replacement and venous thromboembolism following hip and knee arthroplasty. In: Thrombosis and Haemostasis. 2004 ; Vol. 92, No. 2. pp. 337-343.
@article{78bfec1c4aa44cb89a91fffa79df08a3,
title = "Postmenopausal hormone replacement and venous thromboembolism following hip and knee arthroplasty",
abstract = "Hormone replacement therapy has been associated with venous thromboembolism. Controversy exists regarding the appropriate management of hormone replacement in the perioperative setting and in other situations - such as acute illness - predisposing to acute venous thromboembolism. We performed a case-control study to determine whether perioperative hormone replacement is associated with venous thromboembolism following hip and knee arthroplasty. 108 patients with postoperative venous thrombosis were matched by age, date and type of surgery, and surgeon with 210 controls without thrombosis. Perioperative hormone replacement use was no more prevalent in patients with postoperative thrombosis than those without. Eighteen (16.7{\%}) women with post-operative thrombosis had taken perioperative hormone replacement compared to 49 (23.3{\%}) of controls: odds ratio = 0.66; (95{\%} CI 0.35-1.18; p=0.17). After multivariate analysis, the adjusted odds ratios were similar. Variables predicting post-operative thrombosis included: prior venous thromboembolism (OR = 2.3; p = 0.02), rheumatologic disease (OR = 2.2; p = 0.03), and absence of pharmacologic antithrombotic prophylaxis (OR = 13.4; p = 0.005). Cases and controls were otherwise similar. Users of hormone replacement were similar to non-users except that they were less likely to have coronary disease (OR 0.34; p = 0.03) or prior thrombosis (OR = 0.28; p = 0.04), and were younger (median age 67 versus 74 years; p",
keywords = "Arthroplasty, Hormone replacement therapy, Selective oestrogen receptor modulator, Surgery, Venous thromboembolism",
author = "Hurbanek, {Jason G.} and Jaffer, {Amir K.} and Nariman Morra and Matthew Karafa and Daniel Brotman",
year = "2004",
month = "8",
language = "English (US)",
volume = "92",
pages = "337--343",
journal = "Thrombosis and Haemostasis",
issn = "0340-6245",
publisher = "Schattauer GmbH",
number = "2",

}

TY - JOUR

T1 - Postmenopausal hormone replacement and venous thromboembolism following hip and knee arthroplasty

AU - Hurbanek, Jason G.

AU - Jaffer, Amir K.

AU - Morra, Nariman

AU - Karafa, Matthew

AU - Brotman, Daniel

PY - 2004/8

Y1 - 2004/8

N2 - Hormone replacement therapy has been associated with venous thromboembolism. Controversy exists regarding the appropriate management of hormone replacement in the perioperative setting and in other situations - such as acute illness - predisposing to acute venous thromboembolism. We performed a case-control study to determine whether perioperative hormone replacement is associated with venous thromboembolism following hip and knee arthroplasty. 108 patients with postoperative venous thrombosis were matched by age, date and type of surgery, and surgeon with 210 controls without thrombosis. Perioperative hormone replacement use was no more prevalent in patients with postoperative thrombosis than those without. Eighteen (16.7%) women with post-operative thrombosis had taken perioperative hormone replacement compared to 49 (23.3%) of controls: odds ratio = 0.66; (95% CI 0.35-1.18; p=0.17). After multivariate analysis, the adjusted odds ratios were similar. Variables predicting post-operative thrombosis included: prior venous thromboembolism (OR = 2.3; p = 0.02), rheumatologic disease (OR = 2.2; p = 0.03), and absence of pharmacologic antithrombotic prophylaxis (OR = 13.4; p = 0.005). Cases and controls were otherwise similar. Users of hormone replacement were similar to non-users except that they were less likely to have coronary disease (OR 0.34; p = 0.03) or prior thrombosis (OR = 0.28; p = 0.04), and were younger (median age 67 versus 74 years; p

AB - Hormone replacement therapy has been associated with venous thromboembolism. Controversy exists regarding the appropriate management of hormone replacement in the perioperative setting and in other situations - such as acute illness - predisposing to acute venous thromboembolism. We performed a case-control study to determine whether perioperative hormone replacement is associated with venous thromboembolism following hip and knee arthroplasty. 108 patients with postoperative venous thrombosis were matched by age, date and type of surgery, and surgeon with 210 controls without thrombosis. Perioperative hormone replacement use was no more prevalent in patients with postoperative thrombosis than those without. Eighteen (16.7%) women with post-operative thrombosis had taken perioperative hormone replacement compared to 49 (23.3%) of controls: odds ratio = 0.66; (95% CI 0.35-1.18; p=0.17). After multivariate analysis, the adjusted odds ratios were similar. Variables predicting post-operative thrombosis included: prior venous thromboembolism (OR = 2.3; p = 0.02), rheumatologic disease (OR = 2.2; p = 0.03), and absence of pharmacologic antithrombotic prophylaxis (OR = 13.4; p = 0.005). Cases and controls were otherwise similar. Users of hormone replacement were similar to non-users except that they were less likely to have coronary disease (OR 0.34; p = 0.03) or prior thrombosis (OR = 0.28; p = 0.04), and were younger (median age 67 versus 74 years; p

KW - Arthroplasty

KW - Hormone replacement therapy

KW - Selective oestrogen receptor modulator

KW - Surgery

KW - Venous thromboembolism

UR - http://www.scopus.com/inward/record.url?scp=4444364580&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4444364580&partnerID=8YFLogxK

M3 - Article

C2 - 15269830

AN - SCOPUS:4444364580

VL - 92

SP - 337

EP - 343

JO - Thrombosis and Haemostasis

JF - Thrombosis and Haemostasis

SN - 0340-6245

IS - 2

ER -